BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 11012153)

  • 1. Role of the CD34+ 38- cells in posttransplant hematopoietic recovery.
    Hénon P; Sovalat H; Bourderont D; Ojeda-Uribe M; Arkam Y; Wunder E; Raidot JP; Husseini F; Audhuy B
    Stem Cells; 1998; 16 Suppl 1():113-22. PubMed ID: 11012153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Importance of CD34+ cell subsets in autologous PBSC transplantation: the mulhouse experience using CD34+CD38- cells as predictive tool for hematopoietic engraftment.
    Hénon PH; Sovalat H; Bourderont D
    J Biol Regul Homeost Agents; 2001; 15(1):62-7. PubMed ID: 11388746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subsets of CD34+ hematopoietic progenitors and platelet recovery after high dose chemotherapy and peripheral blood stem cell transplantation.
    Meldgaard Knudsen L; Jensen L; Jarlbaek L; Hansen PG; Hansen SW; Drivsholm L; Nikolaisen K; Gaarsdal E; Johnsen HE
    Haematologica; 1999 Jun; 84(6):517-24. PubMed ID: 10366795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of processing four and five times the patients' blood volume during peripheral blood stem cell collection and analysis of CD34+38--and CD34+49d+ subsets during apheresis.
    Bojko P; Scharifi M; Stössel K; Seeber S
    J Cancer Res Clin Oncol; 2002 Jan; 128(1):19-28. PubMed ID: 11862468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD34(+) CD38(-) and CD34(+) HLA-DR(-) cells in BM stem cell grafts correlate with short-term engraftment but have no influence on long-term hematopoietic reconstitution after autologous transplantation.
    Zubair AC; Kao G; Daley H; Schott D; Freedman A; Ritz J
    Cytotherapy; 2006; 8(4):399-407. PubMed ID: 16923616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primordial role of CD34+ 38- cells in early and late trilineage haemopoietic engraftment after autologous blood cell transplantation.
    Hénon P; Sovalat H; Becker M; Arkam Y; Ojeda-Uribe M; Raidot JP; Husseini F; Wunder E; Bourderont D; Audhuy B
    Br J Haematol; 1998 Nov; 103(2):568-81. PubMed ID: 9827938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies.
    Cao TM; Kusnierz-Glaz C; Valone F; Stockerl-Goldstein KE; Hu WW; Johnston L; Blume KG; Strober S; Negrin RS
    Cancer; 2001 Jun; 91(12):2205-13. PubMed ID: 11413507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotypic analysis of early hematopoietic progenitors in cord blood and determination of their correlation with clonogenic progenitors: relevance to cord blood stem cell transplantation.
    Payne TA; Traycoff CM; Laver J; Xu F; Srour EF; Abboud MR
    Bone Marrow Transplant; 1995 Feb; 15(2):187-92. PubMed ID: 7539665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of poor marrow graft function with allogeneic CD34+ cells immunoselected from G-CSF-mobilized peripheral blood progenitor cells of the marrow donor.
    Arseniev L; Tischler HJ; Battmer K; Südmeier I; Casper J; Link H
    Bone Marrow Transplant; 1994 Nov; 14(5):791-7. PubMed ID: 7534162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors influencing hematopoietic recovery after autologous blood stem cell transplantation in patients with acute myeloblastic leukemia and with non-myeloid malignancies.
    Carral A; de la Rubia J; Martín G; Martínez J; Sanz G; Jarque I; Sempere A; Soler MA; Marty ML; Sanz MA
    Bone Marrow Transplant; 2002 May; 29(10):825-32. PubMed ID: 12058232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD34+ cell dose and CD33- subsets: collection and engraftment kinetics in autologous peripheral blood stem cells transplantation.
    Sampol Mayol A; Besalduch Vital J; Galmés Llodrá A; Bargay Lleonart J; Matamoros Flori N; Morey Sureda M; Novo García A; Mascaró Riera M; Gonzaléz Bach E; Martínez García P
    Haematologica; 1998 Jun; 83(6):489-95. PubMed ID: 9676020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD34++ CD38- and CD34+ CD38+ human hematopoietic progenitors from fetal liver, cord blood, and adult bone marrow respond differently to hematopoietic cytokines depending on the ontogenic source.
    Weekx SF; Van Bockstaele DR; Plum J; Moulijn A; Rodrigus I; Lardon F; De Smedt M; Nijs G; Lenjou M; Loquet P; Berneman ZN; Snoeck HW
    Exp Hematol; 1998 Oct; 26(11):1034-42. PubMed ID: 9766443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hematopoietic progenitor cells from allogeneic bone marrow transplant donors circulate in the very early post-transplant period.
    Katayama Y; Mahmut N; Takimoto H; Maeda Y; Yano T; Kojima K; Azuma T; Hara M; Imajyo K; Takahashi S; Kai T; Ohno Y; Miyamoto T; Nagafuji K; Matsue K; Takenaka K; Teshima T; Shinagawa K; Ishimaru F; Omoto E; Harada M
    Bone Marrow Transplant; 1999 Apr; 23(7):659-65. PubMed ID: 10218841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel protocol that allows short-term stem cell expansion of both committed and pluripotent hematopoietic progenitor cells suitable for clinical use.
    Astori G; Malangone W; Adami V; Risso A; Dorotea L; Falasca E; Marini L; Spizzo R; Bigi L; Sala P; Tonutti E; Biffoni F; Rinaldi C; Del Frate G; Pittino M; Degrassi A
    Blood Cells Mol Dis; 2001; 27(4):715-24; discussion 725-7. PubMed ID: 11778655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autografting of highly purified peripheral blood progenitor cells following myeloablative therapy in patients with lymphoma: a prospective study of the long-term effects on tumor eradication, reconstitution of hematopoiesis and immune recovery.
    Dreger P; Viehmann K; von Neuhoff N; Glaubitz T; Petzoldt O; Glass B; Uharek L; Rautenberg P; Suttorp M; Mills B; Mitsky P; Schmitz N
    Bone Marrow Transplant; 1999 Jul; 24(2):153-61. PubMed ID: 10455343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral blood and BM CD34+ CD38- cells show better resistance to cryopreservation than CD34+ CD38+ cells in autologous stem cell transplantation.
    Ojeda-Uribe M; Sovalat H; Bourderont D; Brunot A; Marr A; Lewandowski H; Chabouté V; Peter P; Henon P
    Cytotherapy; 2004; 6(6):571-83. PubMed ID: 15764022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The CD34+90+ cell dose does not predict early engraftment of autologous blood stem cells as well as the total CD34+ cell dose.
    Stewart DA; Guo D; Luider J; Auer I; Klassen J; Morris D; Chaudhry A; Brown C; Russell JA; Gluck S
    Bone Marrow Transplant; 2000 Feb; 25(4):435-40. PubMed ID: 10723588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CXCR4 expression on transplanted peripheral blood CD34+ cells: relationship to engraftment after autologous transplantation in a cohort of multiple myeloma patients.
    Hicks C; Isaacs A; Wong R; Chong BH
    Ann Hematol; 2011 May; 90(5):547-55. PubMed ID: 20957366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pediatric experience with autologous peripheral blood progenitor cell transplantation: influence of CD34+ cell dose in engraftment kinetics.
    Diaz MA; Alegre A; Villa M; Granda A; de la Vega A; Ramirez M; Ruano D; Gonzalez A; Merino JM; Madero L
    Bone Marrow Transplant; 1996 Oct; 18(4):699-703. PubMed ID: 8899183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Failure to achieve a threshold dose of CD34+CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation for multiple myeloma.
    Wallington-Beddoe CT; Gottlieb DJ; Garvin F; Antonenas V; Sartor MM
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1386-93. PubMed ID: 19822297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.